JY
CRNX icon

Jeff Yass’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jeff Yass’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
27,600
-10,700
-28% -$398K ﹤0.01% 8119
2026
Q1 		$1.39M Sell
38,300
-52,100
-58% -$2.33M ﹤0.01% 7081
2025
Q4 		$4.21M Buy
90,400
+45,400
+101% +$2.02M ﹤0.01% 4299
2025
Q3 		$1.87M Buy
+45,000
New +$1.44M ﹤0.01% 5934
2025
Q1 		– Sell
-4,100
Closed -$210K – 12600
2024
Q4 		$210K Sell
4,100
-20,900
-84% -$1.17M ﹤0.01% 10633
2024
Q3 		$1.28M Buy
25,000
+16,200
+184% +$836K ﹤0.01% 6266
2024
Q2 		$394K Sell
8,800
-48,900
-85% -$2.26M ﹤0.01% 8836
2024
Q1 		$2.7M Buy
57,700
+32,500
+129% +$1.27M ﹤0.01% 4709
2023
Q4 		$897K Sell
25,200
-6,400
-20% -$196K ﹤0.01% 7251
2023
Q3 		$940K Buy
31,600
+14,800
+88% +$305K ﹤0.01% 6757
2023
Q2 		$303K Buy
+16,800
New +$335K ﹤0.01% 9414

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's CRNX Position: Q2 2026 in Review

Jeff Yass reduced its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q2 2026, selling an estimated $411K and leaving 35,192 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7492.

Jeff Yass first reported a position in CRNX in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.7M in Q3 2025. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Jeff Yass held 35,192 shares of Crinetics Pharmaceuticals worth $1.32M as of Q2 2026.
  • Jeff Yass sold 11,061 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $411K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7492 holding.
  • Jeff Yass first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Jeff Yass's Crinetics Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.